Eva Dobos

• Dobos, Eva (2017). æpoæiu. Revue de droit uniforme. ISSN 1124-3694.
• Dobos, Eva (2017). evatest. Revue de droit uniforme. ISSN 1124-3694.
• Dobos, Eva (2017). iopuj. Revue de droit uniforme. ISSN 1124-3694.
• Grønning, Terje; Olsen, Dorothy Sutherland; Dobos, Eva; Knell, Mark Stephen & Veistein, Bjørg Kristin (2006). Summary of Country Studies - Norway. In Enzing, Christien (Eds.), Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level. OECD Publishing. ISSN 92-64-01403-9. p. 86–95.

View all works in Cristin

• Dobos, Eva (2017). Plagiat er mer enn bare å kopiere en annens tekst. [Internet]. forskning.no.
• Grønning, Terje; Dobos, Eva & Knell, Mark Stephen (2003). Case study on biotech innovation systems:Norway.
• Grønning, Terje; Dobos, Eva; Knell, Mark Stephen; Veistein, Bjørg Kristin & Olsen, Dorothy Sutherland (2004). CASE STUDY ON BIOTECH INNOVATION SYSTEMS - NORWAY Vol. 1: Biopharmaceuticals. OECD Publishing.
• Grønning, Terje; Dahl, Ingeborg Frogner; Dobos, Eva; Johansson, Ovar Andreas; Knell, Mark Stephen & Olsen, Dorothy Sutherland (2004). CASE STUDY ON BIOTECH INNOVATION SYSTEMS NORWAY Vol. 2: Marine biotechnology. OECD Publishing. Show summary

  This Volume is part of the ?Case Studies in Innovation?, as formulated by the OECD (DSTI/STP/TIP(2002)1). It is, however, a delimited and optional sub-study supplementary to the main case study on biopharmaceuticals. ?Case Studies in Innovation? is ambitiously designed with the aim at answering one main research question: Can we identify important differences and similarities in the structure and dynamics of national biotech innovation system which explains the performance of this system? Then, what are the policy implications of this? Since the sub-study has been conducted on a smaller and non-comparative scale as compared to the main study on biopharmaceuticals, it will not attempt to answer the overall research questions in full. We will, however, aim at presenting an overview of policy aims for this area as well as the current status of marine biotechnology in Norway, and on this basis tentatively sum up some policy implications.

View all works in Cristin